Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-23T19:46:14.007Z Has data issue: false hasContentIssue false

Clinical and neuropathological features of ALS/FTD with TIA1 mutations

Published online by Cambridge University Press:  25 May 2018

V. Hirsch-Reinshagen
Affiliation:
University of British Columbia
AM. Nicholson
Affiliation:
Mayo Clinic
C. Pottier
Affiliation:
Mayo Clinic
M. Baker
Affiliation:
Mayo Clinic
G-YR. Hsiung
Affiliation:
University of British Columbia
C. Krieger
Affiliation:
University of British Columbia
KB. Boylan
Affiliation:
Mayo Clinic
S. Weintraub
Affiliation:
Northwestern University
M. Mesulam
Affiliation:
Northwestern University
E. Bigio
Affiliation:
Northwestern University
L. Zinman
Affiliation:
University of Toronto
J. Keith
Affiliation:
University of Toronto
E. Rogaeva
Affiliation:
University of Toronto
SA. Zivkovic
Affiliation:
University of Pittsburgh
D. Lacomis
Affiliation:
University of Pittsburgh
D. Dickson
Affiliation:
University of Toronto
P. Taylor
Affiliation:
St. Jude Children’s Research Hospital
R. Rademakers
Affiliation:
Mayo Clinic
IR. Mackenzie
Affiliation:
University of British Columbia
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) represent a disease continuum with common genetic causes and molecular pathology. We recently identified mutations in the T-cell restricted intracellular antigen-1 (TIA1) protein as a cause of ALS +/− FTD. TIA1 is an RNA-binding protein containing a low complexity domain (LCD) that promotes the assembly of membrane-less organelles, such as stress granules (SG). Whole exome sequencing of two family members with fALS/FTD revealed a novel missense mutation in the TIA1 LCD (P362L). Subsequent screening identified five more TIA1 mutations in six additional ALS patients, but none in controls. All mutation carriers presented with weakness, behavioral abnormalities or language impairments and had a final diagnosis of ALS +/− FTD. Autopsy on five TIA1 mutation carriers showed widespread neurodegeneration with TDP-43 pathology. Round eosinophilic inclusions in lower motor neurons were a consistent feature. Cellular assays revealed abnormal SG dynamics in the presence of TIA1 mutations. In summary, missense mutations in the LCD of TIA1 are a newly recognized cause of ALS/FTD with TDP-43 pathology and strengthen the role of RNA metabolism in the pathogenesis in this disease.

Type
Abstracts
Copyright
Copyright © The Canadian Journal of Neurological Sciences Inc. 2018